Goldman Sachs
ONCT

Goldman Sachs’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Goldman Sachs’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-249
Closed -$706K – 6826
2013
Q3 		$706K Buy
+249
New +$1.24M ﹤0.01% 4874

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs's ONCT Position: Q4 2022 in Review

Goldman Sachs sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2022, closing a stake of 658 shares — an estimated $12K sold.

Goldman Sachs first reported a position in ONCT in Q2 2013 and held it in 27 quarters. The position peaked at $899K in Q1 2021. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2022.

  • Goldman Sachs reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 658 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $12K.
  • Goldman Sachs first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Goldman Sachs's Oncternal Therapeutics, Inc. Common Stock position peaked at $899K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.